Advancing the Future of RNA-Enhanced Exosomes Therapeutics

Conveyxo is a biotechnology company focused on unlocking the therapeutic power of RNA-enhanced exosomes. Founded in 2019 by experts in cell therapy, biologics, and advanced manufacturing, the company is building a scalable platform that makes next-generation treatments more accessible, more consistent, and more affordable. Conveyxo is revolutionizing large-scale production of RNA-enhanced exosomes by combining cutting-edge manufacturing technology with advanced exosome enrichment systems.

Using its proprietary technology platform, Conveyxo is developing an exclusive therapeutic portfolio to address osteoarthritis and dermatological conditions.
Through strategic partnerships, Conveyxo is also expanding its focus to tackle chronic inflammatory, gut, kidney, and neuro-related diseases.
‍
The mission is simple: bring meaningful therapeutic innovation to patients worldwide.

Our Leadership Team

We were founded and are led by an ambitious team with decades of expertise in pharmaceutical development, biologics and manufacturing. Many of our team have worked together for years and have a strong track-record in drug approvals and commercial success.

Jean-Paul Prieels, Executive Chairman

PhD, served as a Senior Vice President of Research and Development at GSK Biologicals

Frédéric Tonglet, CEO

Commercial Engineer, with a proven track record of success in the finance and biotech sectors over the last 25 years

Tamara Davenne, Translational Science Leader

PhD in Immunology & Translational Medicine  Proven Track record in advancing innovative therapeutics  Strategic leadership in biotech development

Alexandre Lennaertz, Operations Manager

Applied Science Master in the field of virus-like particles (Canada), Demonstrated 10+ years experience in cell and gene therapy process developments and translations to GMP manufacturing.

Hui Yang, CTO

PhD and postdoctoral research in the field of Microsystems (Switzerland). She then joined IMEC in Belgium and late 2017, the Shenzhen Institute of Advanced Technology, part of the Chinese Academy of Sciences. Presently, she is a full professor and leads the Biomedical Microsystems and Nanodevices Group.

Charles Jacques, Chief Finance Officer

10+ years finance experience in CDMO and cell therapy biotech